Ardelyx, Inc. announced that Geoffrey Block, MD, is stepping down from the Board of Directors after nearly five years of service. Dr. Block currently serves as the Associate Chief Medical Director and Senior Vice President of Clinical Research and Medical Affairs at U.S. Renal Care.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.46 USD | +0.62% | -0.77% | +4.19% |
Apr. 17 | Wedbush Raises Price Target on Ardelyx to $14 From $13, Keeps Outperform Rating | MT |
Apr. 05 | Leerink Partners Initiates Coverage on Ardelyx With Outperform Rating, $14 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.19% | 1.5B | |
-2.63% | 102B | |
+1.62% | 96.29B | |
+1.46% | 22.18B | |
-16.67% | 21.2B | |
-8.58% | 18.31B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- ARDX Stock
- News Ardelyx, Inc.
- Ardelyx Announces Departure of Geoffrey Block as Board Member